Core Scientific Q3 2026 Earnings: Colocation Scale Drives Margin Expansion

Core Scientific (NASDAQ: CORZ) reported Q3 2026 revenue of $232.9 million, up 187% from $81.1 million a year earlier, while diluted EPS swung to $0.47 from a loss of $0.45. Colocation revenue reached $215.4 million and lifted consolidated gross margin to 53%, although reported net income of $1.18 billion was primarily driven by a non-cash fair-value gain.

Core Earnings Data

Colocation expansion drove most of the year-over-year improvement. Gross profit rose to $123.3 million from $3.9 million, and the gross margin increased by 48 percentage points as the higher-margin colocation business became the company’s dominant source of revenue.

Operating income reached $72.4 million, compared with a $54.8 million loss. The much larger swing in net income mainly reflected a $1.03 billion non-cash gain from changes in the fair value of warrants and contingent value rights, so adjusted EBITDA provides a clearer view of underlying operating progress.

Capital expenditures include purchases of property, plant and equipment as well as acquisitions of land and development rights.

Business and Segment Performance

Colocation generated about 93% of total quarterly revenue and more than offset continued contraction in the company’s legacy digital asset businesses. Billing capacity increased from 395 MW in Q2 to 485 MW at quarter-end, supporting a nearly 60% sequential increase in colocation revenue.

Colocation license fees contributed $157.3 million, while customer power pass-through fees contributed $57.6 million. The 485 MW under billing represented more than $700 million of average annualized GAAP colocation revenue, which is a run-rate measure rather than revenue recognized during the quarter.

Digital asset self-mining revenue fell about 79% year over year and remained gross-margin negative. Hosted mining revenue also declined, but its gross margin improved to 46% from 23% as costs fell faster than revenue.

Colocation Scale Lifted Margins While Expansion Consumed Capital

The transition toward colocation changed Core Scientific’s operating economics. The segment produced $128.4 million of gross profit at a 60% margin, more than offsetting the $7.5 million gross loss from self-mining. This mix shift explains much of the increase in consolidated gross margin and adjusted EBITDA.

The expansion remains capital intensive. Q3 capital expenditures reached $985.1 million, while liquidity and debt service reserve accounts declined to $1.74 billion from $2.60 billion in Q2. Cash and cash equivalents fell to $803.9 million from $1.77 billion over the same period, and long-term debt stood at $4.30 billion at quarter-end.

Cash-flow figures were provided only for the first nine months of 2026, not for Q3 alone. Nine-month operating cash flow was $296.2 million, up from $120.7 million a year earlier, but investing cash outflow reached $2.17 billion as the company invested in facilities and asset acquisitions. Financing activities supplied a net $3.20 billion during the period, including $4.28 billion of debt issuance and $1.00 billion of debt-extinguishment payments.

Management’s View

CEO Adam Sullivan said the company was nearing full delivery under its first colocation agreement, while construction under its second agreement was underway across five campuses. Management attributed the sequential revenue growth to additional billing megawatts and said substantial contracted capacity remains to be delivered.

Recent Insider Transactions

Over the last six months, insiders purchased 324,176 shares across seven transactions and sold 260,000 shares across 26 transactions, resulting in net purchases of 64,176 shares. The latest 10 reported entries consisted of nine sales by officer Todd M. Duchene and one purchase by director Eric Stanton Weiss; the transactions do not by themselves establish the insiders’ motives.

Risks Investors Should Watch

• Non-cash accounting volatility: The $1.03 billion fair-value gain was the main driver of reported net income. Future changes in warrant values could create substantial swings that do not reflect operating performance.
• Heavy capital requirements: Quarterly capital expenditures of $985.1 million exceeded nine-month operating cash flow, while cash and liquidity declined sequentially. Continued construction requires careful funding and execution.
• Leverage: Long-term debt totaled $4.30 billion at quarter-end, increasing the importance of successfully delivering contracted colocation capacity and converting it into cash flow.
• Construction and delivery execution: The second colocation agreement involves work across five campuses. Delays in construction, power availability, equipment procurement or customer delivery could affect the timing of revenue recognition.
• Legacy mining losses: Self-mining revenue contracted sharply and produced a negative 61% gross margin, leaving the business as a continuing drag during the colocation transition.

Summary

Core Scientific’s Q3 2026 results show that colocation has become the central earnings engine, driving higher revenue, gross margin and adjusted EBITDA despite continued weakness in digital asset mining. The next phase depends on converting contracted capacity into billed megawatts while managing substantial construction spending, reduced liquidity and a larger debt balance. Investors should separate the underlying operating improvement from the non-cash warrant gain that dominated GAAP net income.